Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
public_traded
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd is publicly traded on SHH under ticker 688336.SS.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor for rheumatism; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody injection; Cipterbin, an anti-HER2 monoclonal antibody. The company is also developing products for autoimmune diseases, tumors, and other diseases. The company was founded in 2002 and is based in Shanghai, China.